Journal of Pathology and Translational Medicine (대한병리학회지)

The Korean Society of Pathologists (대한병리학회)
권호 표지
DOI QR코드

DOI QR Code

High Cytoplasmic CXCR4 Expression Predicts Prolonged Survival in Triple-Negative Breast Cancer Patients Treated with Adjuvant Chemotherapy

  • Shim, Bobae (Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine) ;
  • Jin, Min-Sun (Department of Pathology, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Moon, Ji Hye (Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine) ;
  • Park, In Ae (Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine) ;
  • Ryu, Han Suk (Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine)
  • Received : 2018.08.07
  • Accepted : 2018.09.18
  • Published : 2018.11.15
⟨ Previous Next ⟩

Abstract

Background: Chemokine receptor CXC chemokine receptor type 4 (CXCR4) and its ligand CXC motif chemokine 12 (CXCL12; stromal cell-derived factor-1) are implicated in tumor growth, metastasis, and tumor cell-microenvironment interaction. A number of studies have reported that increased CXCR4 expression is associated with worse prognosis in triple-negative breast cancer (TNBC), but its prognostic significance has not been studied in TNBC patients treated with adjuvant chemotherapy. Methods: Two hundred eighty-three TNBC patients who received adjuvant chemotherapy were retrospectively analyzed. Tissue microarray was constructed from formalin-fixed, paraffin-embedded tumor tissue and immunohistochemistry for CXCR4 and CXCL12 was performed. Expression of each marker was compared with clinicopathologic characteristics and outcome. Results: High cytoplasmic CXCR4 expression was associated with younger age (p=.008), higher histologic grade (p=.007) and lower pathologic stage (p=.045), while high CXCL12 expression was related to larger tumor size (p=.045), positive lymph node metastasis (p=.005), and higher pathologic stage (p=.017). The patients with high cytoplasmic CXCR4 experienced lower distant recurrence (p=.006) and better recurrence-free survival (RFS) (log-rank p=.020) after adjuvant chemotherapy. Cytoplasmic CXCR4 expression remained an independent factor of distant recurrence (p=.019) and RFS (p=.038) after multivariate analysis. Conclusions: High cytoplasmic CXCR4 expression was associated with lower distant recurrence and better RFS in TNBC patients treated with adjuvant chemotherapy. This is the first study to correlate high CXCR4 expression to better TNBC prognosis, and the underlying mechanism needs to be elucidated in further studies.

Keywords

References

  1. Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol 2012; 23 Suppl 6: vi7-12.
  2. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triplenegative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 2016; 13: 674-90. https://doi.org/10.1038/nrclinonc.2016.66
  3. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004; 4: 540-50. https://doi.org/10.1038/nrc1388
  4. Nagasawa T, Hirota S, Tachibana K, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996; 382: 635-8. https://doi.org/10.1038/382635a0
  5. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998; 392: 565-8. https://doi.org/10.1038/33340
  6. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998; 393: 595-9. https://doi.org/10.1038/31269
  7. Domanska UM, Kruizinga RC, Nagengast WB, et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer 2013; 49: 219-30. https://doi.org/10.1016/j.ejca.2012.05.005
  8. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 335-48. https://doi.org/10.1016/j.cell.2005.02.034
  9. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-6. https://doi.org/10.1038/35065016
  10. Liu Y, Ji R, Li J, et al. Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis. J Exp Clin Cancer Res 2010; 29: 16. https://doi.org/10.1186/1756-9966-29-16
  11. Zhang Z, Ni C, Chen W, et al. Expression of CXCR4 and breast cancer prognosis: a systematic review and meta-analysis. BMC Cancer 2014; 14: 49. https://doi.org/10.1186/1471-2407-14-49
  12. Smith MC, Luker KE, Garbow JR, et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004; 64: 8604-12. https://doi.org/10.1158/0008-5472.CAN-04-1844
  13. Huang EH, Singh B, Cristofanilli M, et al. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res 2009; 155: 231-6. https://doi.org/10.1016/j.jss.2008.06.044
  14. Chu QD, Panu L, Holm NT, Li BD, Johnson LW, Zhang S. High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome. J Surg Res 2010; 159: 689-95. https://doi.org/10.1016/j.jss.2008.09.020
  15. Yu S, Wang X, Liu G, Zhu X, Chen Y. High level of CXCR4 in triplenegative breast cancer specimens associated with a poor clinical outcome. Acta Med Okayama 2013; 67: 369-75.
  16. Chen HW, Du CW, Wei XL, Khoo US, Zhang GJ. Cytoplasmic CXCR4 high-expression exhibits distinct poor clinicopathological characteristics and predicts poor prognosis in triple-negative breast cancer. Curr Mol Med 2013; 13: 410-6.
  17. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-95. https://doi.org/10.1200/JCO.2009.25.6529
  18. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31: 3997-4013. https://doi.org/10.1200/JCO.2013.50.9984
  19. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-10. https://doi.org/10.1111/j.1365-2559.1991.tb00229.x
  20. Hudis CA, Barlow WE, Costantino JP, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 2007; 25: 2127-32. https://doi.org/10.1200/JCO.2006.10.3523
  21. Guo F, Wang Y, Liu J, Mok SC, Xue F, Zhang W. CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks. Oncogene 2016; 35: 816-26. https://doi.org/10.1038/onc.2015.139
  22. Haribabu B, Richardson RM, Fisher I, et al. Regulation of human chemokine receptors CXCR4. Role of phosphorylation in desensitization and internalization. J Biol Chem 1997; 272: 28726-31. https://doi.org/10.1074/jbc.272.45.28726
  23. Salvucci O, Bouchard A, Baccarelli A, et al. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat 2006; 97: 275-83. https://doi.org/10.1007/s10549-005-9121-8
  24. Hassan S, Ferrario C, Saragovi U, et al. The influence of tumor-host interactions in the stromal cell-derived factor-1/CXCR4 ligand/receptor axis in determining metastatic risk in breast cancer. Am J Pathol 2009; 175: 66-73. https://doi.org/10.2353/ajpath.2009.080948
  25. Guembarovski AL, Guembarovski RL, Hirata BK, et al. CXCL12 chemokine and CXCR4 receptor: association with susceptibility and prognostic markers in triple negative breast cancer. Mol Biol Rep 2018 Jun 20 [Epub]. https://doi.org/10.1007/s11033-018-4215-7.
  26. Kobayashi T, Tsuda H, Moriya T, et al. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis. Breast Cancer Res Treat 2010; 123: 733-45. https://doi.org/10.1007/s10549-009-0672-y
  27. Mirisola V, Zuccarino A, Bachmeier BE, et al. CXCL12/SDF1 expression by breast cancers is an independent prognostic marker of diseasefree and overall survival. Eur J Cancer 2009; 45: 2579-87. https://doi.org/10.1016/j.ejca.2009.06.026
  28. Yan M, Jene N, Byrne D, et al. Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Res 2011; 13: R47. https://doi.org/10.1186/bcr2869
  29. Kang H, Watkins G, Parr C, Douglas-Jones A, Mansel RE, Jiang WG. Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. Breast Cancer Res 2005; 7: R402-10.
  30. Samarendra H, Jones K, Petrinic T, et al. A meta-analysis of CXCL12 expression for cancer prognosis. Br J Cancer 2017; 117: 124-35. https://doi.org/10.1038/bjc.2017.134
  31. Lefort S, Thuleau A, Kieffer Y, et al. CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients. Oncogene 2017; 36: 1211-22. https://doi.org/10.1038/onc.2016.284
  32. Lebert JM, Lester R, Powell E, Seal M, McCarthy J. Advances in the systemic treatment of triple-negative breast cancer. Curr Oncol 2018; 25(Suppl 1): S142-S50. https://doi.org/10.3747/co.25.3954